Dizhe Pharmaceutical: Voluntary disclosure of the announcement that Schwarzhe's first-line treatment for EGFR 20 exon insertion mutant advanced non-small cell lung cancer was recognized as a breakthrough treatment by the US FDA

SZSI · Apr 8

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

迪哲医药：自愿披露关于舒沃哲一线治疗EGFR 20号外显子插入突变型晚期非小细胞肺癌获美国FDA突破性疗法认定的公告

Dizhe Pharmaceutical: Voluntary disclosure of the announcement that Schwarzhe's first-line treatment for EGFR 20 exon insertion mutant advanced non-small cell lung cancer was recognized as a breakthrough treatment by the US FDA

Risk Disclaimer

Statement